172 related articles for article (PubMed ID: 2284891)
1. Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs.
Kawai K; Suzuki S; Ohashi S; Mukai H; Murayma Y; Yamashita K
Acta Endocrinol (Copenh); 1990 Dec; 123(6):661-7. PubMed ID: 2284891
[TBL] [Abstract][Full Text] [Related]
2. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
3. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration.
Hargrove DM; Nardone NA; Persson LM; Parker JC; Stevenson RW
Metabolism; 1995 Sep; 44(9):1231-7. PubMed ID: 7666800
[TBL] [Abstract][Full Text] [Related]
4. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
Suzuki S; Kawai K; Ohashi S; Mukai H; Murayama Y; Yamashita K
Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
[TBL] [Abstract][Full Text] [Related]
5. Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.
Suzuki S; Kawai K; Ohashi S; Watanabe Y; Yamashita K
Metabolism; 1992 Apr; 41(4):359-63. PubMed ID: 1556941
[TBL] [Abstract][Full Text] [Related]
6. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
Deacon CF; Plamboeck A; Møller S; Holst JJ
Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
Ritzel R; Orskov C; Holst JJ; Nauck MA
Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
10. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
[TBL] [Abstract][Full Text] [Related]
11. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
12. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 does not not acutely affect insulin sensitivity in healthy man.
Orskov L; Holst JJ; Møller J; Orskov C; Møller N; Alberti KG; Schmitz O
Diabetologia; 1996 Oct; 39(10):1227-32. PubMed ID: 8897012
[TBL] [Abstract][Full Text] [Related]
14. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
Nikolaidis LA; Elahi D; Shen YT; Shannon RP
Am J Physiol Heart Circ Physiol; 2005 Dec; 289(6):H2401-8. PubMed ID: 16024574
[TBL] [Abstract][Full Text] [Related]
15. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
[TBL] [Abstract][Full Text] [Related]
16. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
[TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
18. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
Vahl TP; Paty BW; Fuller BD; Prigeon RL; D'Alessio DA
J Clin Endocrinol Metab; 2003 Apr; 88(4):1772-9. PubMed ID: 12679472
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
Vella A; Shah P; Basu R; Basu A; Holst JJ; Rizza RA
Diabetes; 2000 Apr; 49(4):611-7. PubMed ID: 10871199
[TBL] [Abstract][Full Text] [Related]
20. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
